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INTRODUCTION
Survival estimates of patients registered by population-
based cancer registries reflect the average prognosis from a
given cancer, since they are based on unselected patients with
a variety of natural histories as well as treatment patterns.
Population-based cancer survival data are also useful for eval-
uating effectiveness and efficiency of cancer-directed health
services in a given region. Although survival data have been
reported for selected cancer sites from hospitals, the survival
data from population-based registry data have been rarely
reported in Korea (1, 2).
The Korea Central Cancer Registry (KCCR) began as a
nationwide hospital-based program in 1980. The operational
details of cancer registration have been previously described
(3). The KCCR constructed the Korea National Cancer Inci-
dence DataBases (KNCIDB) by merging the KCCR data-
bases and eight Population-Based Regional Cancer Registry
databases, the site-specific cancer registry databases (breast,
ovary, uterus, and liver cancer) and additional data from
medical record review surveys. Using this KNCIDB and
other sources such as mortality data from National Statisti-
cal Office, it became possible to produce national survival
rates. In this paper, we report the results from survival analy-
sis for cancer patients diagnosed during 1993-2002 in Korea
at primary cancer sites.
MATERIALS AND METHODS
The data in this study were based on the KNCIDB. A total
of 935,325 cancer patients diagnosed from January 1, 1993
to December 31, 2002 were included. 
Table 1 shows the quality indices, numbers and proportion
of included and excluded cases. The Morphological Verifica-
tion (MV) %, an indicator of the validity of the diagnostic
information, is the percentage of cases for which the diagno-
sis was based on morphological verification of a tissue speci-
men. Overall, MV% was 69.3% (n=648,615), ranging from
22.2% in liver to 94.7% in thyroid. Death certificate only
(DCO) % was the percent of cancer cases recognized by only
the mortality records, which is another indicator for the vali-
dity of the data. Overall, DCO% was 13.5% (n=126,702),
ranging from 0.5% in Corpus uteri to 24.7% in Brain and
CNS. 
A total of 126,702 DCO cases (13.5%) were excluded from
the survival analysis. Furthermore, 7,886 cases (0.8%), that
could not be followed up due to mismatched Personal Iden-
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Cancer Survival in Korea 1993-2002: A Population-Based Study
Population-based survival reflect the average prognosis of unselected patients with
a variety of natural histories as well as treatment patterns and are also useful for
evaluating effectiveness and efficiency of cancer-directed health services in a given
region. Although survival data have been reported based on hospital data, the sur-
vival data from population-based registry have been rarely reported in Korea. Based
on the Korea National Cancer Incidence Database, we report the results from sur-
vival analysis for cancer patients diagnosed during 1993-2002 and followed up until
31 December 2005 at primary cancer sites. The five-year relative survival rates
(RSR) were calculated using the Ederer II method. The Kaplan-Meier method was
used to estimate median survival and the  95% confidence intervals. In males, the
five-year RSR for all cancers was 32.5% during 1993-1997 and was 37.8% during
1998-2002. In females, the five-year RSR for all cancers was 53.7% during 1993-
1997 and was 57.0% during 1998-2002. The largest improvement in survival was
shown in prostate cancer in males and breast and stomach cancer in females. The
median survival durations were 16.3 months in males and 81.6 months in females.
This result will be useful for evaluation of cancer treatment outcomes in Korea. 
Key Words : Cancer Registry; Survival; Korea 
Received : 14 September 2006
Accepted : 18 December 2006S6 K.-W. Jung, S.-H. Yim, H.-J. Kong, et al.
tification Number, 19,074 cases (2.0%), that were not first
primary sites, and 1,390 cases (0.1%) with mismatched dates
were excluded from the analysis. 
A total of 780,273 cases (83.4%) were eligible for final
analysis. Passive follow-up was performed until 31 Decem-
ber 2005. The survival duration of each case was determined
as the time difference (in months) from the date of initial
diagnosis to the date of death, date of loss to follow-up, or
the closing date for follow-up. Cancer was classified accord-
ing to the International Classification of Diseases, the 10th
revision (ICD-10).
Five-year relative survival rates (RSRs) and the median
survival time were calculated. Relative survival was defined
as the ratio of the observed survival rate to the expected rate;
this was based on a group of people in the general popula-
tion similar to the patient group with respect to race, sex,
age and calendar period of observation (4). It means the sur-
vival experience of patients are adjusted for normal life expec-
tancy of the general population of the same age, which makes
relative survival rate an estimate of the chance of surviving
the effects of cancer  (5). 
The RSRs were calculated using the Ederer II method (6).
Relative survival analyses were based on an algorithm written
in SAS by Paul Dickman (7) with some minor adaptations.
Asymmetric observed survival confidence intervals (CIs) were
formed from standard errors estimated using the Greenwood’s
method (8) and the log (-log) transformation. RSR confidence
limits were derived by dividing the observed survival limits
by the corresponding expected survival rate (4). 
The median survival using the Kaplan-Meier method and
its CIs were also calculated (8).
RESULTS
Relative survival (Table 2, Fig. 1, 2)
In males, the five-year RSR for all cancers combined was
32.5% (95% CI 32.2-32.7) during the period 1993-1997
and was 37.8% (95% CI 37.6-38.0) during 1998-2002. In
females, the five-year RSR for all cancers was 53.7% (95%
CI 53.4-53.9) during 1993-1997 and was 57.0% (95% CI
56.8-57.2) during 1998-2002.
The 10 most common cancer sites in males were stomach,
liver, lung, colon and rectum, bladder, esophagus, gallblad-
der, pancreas, prostate, and oral cavity & pharynx and five-
year RSRs for these cancer sites were 43.8% (95% CI 43.3-
44.3), 10.4% (95% CI 10.1-10.8), 10.5% (95% CI 10.1-
10.9), 56.0% (95% CI 55.1-57.0), 72.6% (95% CI 71.0-
74.1), 12.3% (95% CI 11.4-13.2), 17.6% (95% CI 16.5-
Sites ICD-10
Quality indices
MV% DCO%
Total 
registered
No. of excluded cases
DCO
Lost to
follow-up
Multiple
primary
Date
error
No. of included cases
Years
1993-1997
Years
1998-2002
Oral cavity & pharynx C00-C14 16,399 84.0  8.7  1,421 190 293 24 6,068 8,403
Esophagus C15 17,964 74.3 16.4  2,951 119 168 29 6,248 8,449
Stomach C16 201,945 77.3 15.9 32,032 1,603 710 248 69,401 97,951
Colon & rectum C18-C20 84,151 84.4  7.4  6,233 589 1,920 112 26,034 49,263
Liver C22 126,833 22.2 22.3 28,271 979 1,358 203 37,811 58,211
Gallbladder C23-C24 28,253 49.0 12.9  3,639 251 990 51 9,284 14,038
Pancreas C25 23,872 35.1 19.5  4,655 167 564 44 6,789 11,653
Larynx C32 10,884 73.8 18.1  1,966 88 475 8 3,668 4,679
Lung C33-C34 120,423 66.1 17.7 21,345 874 2,199 213 37,049 58,743
Breast C50 50,468 92.9 3.1 1,585 346 502 37 17,389 30,609
Cervix uteri C53 44,508 93.3  1.7  756 554 833 52 21,022 21,291
Corpus uteri C54 5,621 96.6  0.5  28 78 374 7 1,690 3,446
Ovary C56 11,389 84.2 5.7  650 124 546 19 4,058 5,992
Prostate C61 11,198 84.6 5.3  590 67 420 8 3,194 6,919
Testis C62 1,117 92.3 2.0  22 17 10 1 408 659
Kidney C64 12,062 78.0 6.5  788 79 547 13 3,872 6,763
Bladder C67 19,364 86.2 6.4 1,231 164 977 22 6,550 10,420
Brain & CNS C70-C72 13,241 57.1  24.7  3,276 177 177 35 4,105 5,471
Thyroid C73 28,219 94.7 1.5  437 215 833 24 8,794 17,916
NHL C82-C85, C96 18,958 88.5  10.6  2,019 182 713 29 6,261 9,754
Leukemia C91-C95 18,745 85.3 14.4  2,690 2,126 253 51 6,693 8,846
All other cancers Re C00-C97 69,711 70.8  14.5  10,117 811 4,214 160 22,996 31,413
All cancers but skin C00-C97 except C44 926,497 69.2 13.6 126,063 7,758 18,504 1,379 306,637 466,156
All cancers C00-C97 935,325 69.3  13.5  126,702 7,886 19,074 1,390 309,384 470,889
Table 1. Data quality indices, numbers and proportion of included and excluded cases
CNS, central nervous system; NHL, non-Hodgkin’s lymphoma; MV, Morphological verification; DCO, death certificate only.18.9), 7.7% (95% CI 6.8-8.6), 59.1% (95% CI 56.7-61.5),
and 36.4% (95% CI 34.9-37.9) during 1993-1997, and
were 50.3% (95% CI 49.8-50.7), 14.5% (95% CI 14.2-
14.9), 12.4% (95% CI 12.0-12.7), 61.7% (95% CI 61.0-
62.5), 76.2% (95% CI 74.9-77.4), 16.0% (95% CI 15.1-
17.0), 21.4% (95% CI 20.3-22.5), 7.4% (95% CI 6.7-8.1),
70.6% (95% CI 68.9-72.3), and 42.7% (95% CI 41.3-44.1)
during 1998-2002, respectively. 
In the females, the 10 most common cancer sites were sto-
mach, breast, cervix uteri, colon and rectum, lung, thyroid,
liver, gallbladder, ovary, pancreas, and the five-year RSRs for
these cancer sites were 43.0% (95% CI 42.3-43.6), 79.6%
(95% CI 79.0-80.3), 78.7% (95% CI 78.1-79.3), 53.9%
(95% CI 52.9-54.9), 14.2% (95% CI 13.5-15.0), 95.2%
(95% CI 94.6-95.8), 13.1% (95% CI 12.4-13.9), 18.1%
(95% CI 16.9-19.3), 58.3% (95% CI 56.7-59.9), 8.8%
(95% CI 7.7-9.9) during 1993-1997, and were 48.7%
(95% CI 48.1-49.3), 85.0% (95% CI 84.5-85.4), 80.4%
(95% CI 79.8-81.0), 59.1% (95% CI 58.4-59.9), 17.4%
(95% CI 16.8-18.1), 96.7% (95% CI 96.3-97.1), 15.3%
(95% CI 14.7-16.0), 19.4% (95% CI 18.4-20.4), 60.0%
(95% CI 58.7-61.4), and 7.1% (95% CI 6.3-7.9) during
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Fig. 1. Five-year relative survival of 10 major cancers in Korea,
male, 1993-2002.
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Fig. 2. Five-year relative survival of 10 major cancers in Korea,
female, 1993-2002.
1998-2002
Sites
Year 1993-1997
Male Female
Year 1998-2002
Male Female
Oral cavity & pharynx 36.4 (34.9, 37.9) 60.4 (57.6, 63.0) 42.7 (41.3, 44.1) 63.6 (61.2, 65.8)
Esophagus 12.3 (11.4, 13.2) 21.8 (18.1, 25.7) 16.0 (15.1, 17.0) 24.9 (21.3, 28.6)
Stomach 43.8 (43.3, 44.3) 43.0 (42.3, 43.6) 50.3 (49.8, 50.7) 48.7 (48.1, 49.3)
Colon & rectum 56.0 (55.1, 57.0) 53.9 (52.9, 54.9) 61.7 (61.0, 62.5) 59.1 (58.4, 59.9)
Liver 10.4 (10.1, 10.8) 13.1 (12.4, 13.9) 14.5 (14.2, 14.9) 15.3 (14.7, 16.0)
Gallbladder 17.6 (16.5, 18.9) 18.1 (16.9, 19.3) 21.4 (20.3, 22.5) 19.4 (18.4, 20.4)
Pancreas 7.7 (6.8, 8.6) 8.8 (7.7, 9.9) 7.4 (6.7, 8.1) 7.1 (6.3, 7.9)
Larynx 61.3 (59.4, 63.3) 57.6 (51.4, 63.4) 64.4 (62.6, 66.1) 56.2 (50.4, 61.7)
Lung 10.5 (10.1, 10.9) 14.2 (13.5, 15.0) 12.4 (12.0, 12.7) 17.4 (16.8, 18.1)
Breast 77.4 (67.4, 85.9) 79.6 (79.0, 80.3) 89.6 (81.1, 96.3) 85.0 (84.5, 85.4)
Cervix uteri - 78.7 (78.1, 79.3) - 80.4 (79.8, 81.0)
Corpus uteri - 80.6 (78.5, 82.6) - 82.9 (81.5, 84.3)
Ovary - 58.3 (56.7, 59.9) - 60.0 (58.7, 61.4)
Prostate 59.1 (56.7, 61.5) - 70.6 (68.9, 72.3) -
Testis 86.3 (82.3, 89.5) - 89.7 (86.8, 92.0) -
Kidney 62.1 (59.9, 64.1) 65.5 (62.6, 68.2) 67.9 (66.3, 69.5) 71.8 (69.6, 73.8)
Bladder 72.6 (71.0, 74.1) 65.1 (62.0, 68.1) 76.2 (74.9, 77.4) 66.3 (63.8, 68.7)
Brain & CNS 36.7 (34.7, 38.7) 38.1 (35.8, 40.4) 36.3 (34.5, 38.2) 40.6 (38.6, 42.6)
Thyroid 87.5 (85.2, 89.5) 95.2 (94.6, 95.8) 91.3 (89.7, 92.7) 96.7 (96.3, 97.1)
NHL 46.8 (45.1, 48.5) 50.7 (48.7, 52.8) 51.8 (50.3, 53.2) 56.1 (54.4, 57.8)
Leukemia 28.1 (26.7, 29.6) 30.4 (28.7, 32.1) 35.7 (34.3, 37.1) 37.1 (35.5, 38.6)
All other cancers 37.6 (36.7, 38.5) 45.7 (44.7, 46.7) 43.6 (42.7, 44.4) 48.8 (47.9, 49.8)
All cancers except skin 32.1 (31.8, 32.3) 53.3 (53.1, 53.6) 37.4 (37.2, 37.6) 56.6 (56.4, 56.9)
All cancers 32.5 (32.2, 32.7) 53.7 (53.4, 53.9) 37.8 (37.6, 38.0) 57.0 (56.8, 57.2)
Table 2. Five-year relative survival rates and 95% confidence intervals by cancer site and sex                                      Unit: % (95% CI)
CNS, central nervous system; NHL, non-Hodgkin’s lymphoma.1998-2002, respectively. The largest improvement in sur-
vival was shown in prostate cancer in males, and stomach
and breast cancer in females. Most cancers diagnosed during
1998-2002 had higher relative survival than during 1993-
1997, except for pancreatic cancer.
Median survival (Table 3)
The median survival time by sex was shown in Table 3. The
median follow-up time was 16.3 months in males and 44.4
months in females.
The median survival time for all cancer patients was 16.3
months in males and 81.6 months in females. Female cancer
patients survived significantly longer than male cancer patients.
The median survival time for stomach, liver, lung, and colon
and rectal cancer in males were 30.9 (95% CI 30.2-31.5), 5.8
(95% CI 5.7-5.9), 7.6 (95% CI 7.6-7.7), and 68.2 (95% CI
66.2-70.3) months, respectively. In females, the median sur-
vival time for stomach, colon and rectum, lung, and liver
cancer patients were 31.8 (95% CI 30.9-33.0), 72.6 (95%
CI 69.9-75.8), 8.9 (95% CI 8.7-9.1), and 6.6 (95% CI 6.4-
6.7) months, respectively. The median survival of breast and
uterine cervical cancer in females were not calculated because
of the high survival rates. The median survival for pancreatic
cancer was the lowest.
DISCUSSION
Monitoring the survival trends of cancer patients is essen-
tial for assessment of the progress in cancer treatment (9).
However, reports on survival are limited especially in devel-
oping countries (10, 11); in Korea, there is only one article
on population-based survival of cancer patients diagnosed in
1995 (1). 
This study first reports that survival rates for cancer pa-
tients have improved substantially in Korea during the last
decade.
For all cancers combined, females appeared to have a much
better prognosis than males, which has been previously ob-
served in other countries (12). This apparent female advan-
tage is partly explained by the high frequency of female can-
cers (e.g., thyroid, breast, and uterine cervix) known to have
relatively good prognosis. In addition, it is possible that be-
havioral, environmental, and genetic factors and their com-
plex interrelations, may influence cancer prognosis, and play
a role in determining the survival differences between males
and females found in the present study (13). 
Cancer survival improved steadily for most cancers in both
sexes between 1993-1997 and 1998-2002. For males, the
five-year survival increased between 1993 and 2002 for most
cancers except for pancreas, brain and central nervous system.
S8 K.-W. Jung, S.-H. Yim, H.-J. Kong, et al.
Sites
Male
Median survival
(95% CI)
Median FU
in months
No.
Female
Median survival
(95% CI)
Median FU
in months
No.
Oral cavity & pharynx 10,972 25.4  25.4 (24.5, 26.5) 3,499 52.0  118.0 (105.4, 132.3)
Esophagus 13,492 9.1  9.1 (8.9, 9.2) 1,205 10.8  10.8 (9.8, 11.7)
Stomach 111,165 30.9  30.9 (30.2, 31.5) 56,187 31.8  31.8 (30.9, 33.0)
Colon & rectum 41,463 44.3  68.2 (66.2, 70.3) 33,834 45.1  72.6 (69.9, 75.8)
Liver 73,426 5.8  5.8 (5.7, 5.9) 22,596 6.6  6.6 (6.4, 6.7)
Gallbladder 11,735 8.6  8.6 (8.3, 8.9) 11,587 7.7  7.7 (7.5, 8.0)
Pancreas 10,740 4.4  4.4 (4.2, 4.5) 7,702 4.6  4.6 (4.4, 4.7)
Larynx 7,615 48.8  78.5 (73.4, 83.2) 732 46.3  62.1 (49.4, 74.9)
Lung 72,446 7.6  7.6 (7.6, 7.7) 23,346 8.9  8.9 (8.7, 9.1)
Breast 325 60.6  126.7 (110.3, -) 47,673 65.5  NA
Cervix uteri - - - 42,313 75.5  NA
Corpus uteri - - - 5,136 65.0  NA
Ovary - - - 10,050 51.8  123.0 (108.9, 141.7)
Prostate 10,113 44.6  58.2 (56.4, 60.4) - - -
Testis 1,067 74.4 NA - - -
Kidney 7,173 49.8  119.4 (110.5, 126.0) 3,462 54.8  NA
Bladder 13,592 55.3  117.8 (111.0, 124.6) 3,378 50.8  102.5 (89.4, 120.5)
Brain & CNS 5,282 20.2  20.2 (18.9, 21.9) 4,294 23.7  23.7 (21.7, 26.2)
Thyroid 3,923 68.7 NA 22,787 71.3  NA
NHL 9,560 37.9  41.4 (38.3, 45.7) 6,455 43.0  67.4 (60.3, 77.8)
Leukemia 8,729 16.2  16.2 (15.4, 16.9) 6,810 16.1  16.1 (15.2, 17.2)
All other cancers 29,618 20.4  20.4 (19.5, 21.1) 24,791 36.0  36.0 (34.3, 38.0)
All cancers except skin 438,736 16.0 16.0 (15.8, 16.1) 334,057 44.2 79.5 (77.8, 81.2)
All cancers 442,436 16.3  16.3 (16.2,16.4) 337,837 44.4  81.6 (80.0, 83.3)
Table 3. Median survival and 95% confidence intervals (in months) by cancer site and gender during the period 1993-2002
CNS, Central nervous system; NHL, Non-Hodgkin’s lymphoma; NA, Not available, If more than 50% of the subjects are alive at the end of the study,
then median survival cannot be computed; FU, Follow up; CI, Confidence interval.For females, the five-year survival increased for most cancers
during the same period except for pancreas and larynx.
The greatest survival improvement was observed in pro-
state cancer. The five-year relative survival rate increased
from 59.1% to 70.6% between 1993 and 2002. These rapid
increases should be interpreted with caution. Widespread
use of Prostate Specific Antigen (PSA) test in Korea may have
led to diagnosis and treatment of many asymptomatic pro-
state cancers that might never have been diagnosed during
a man’s lifetime (14). This has led to a rapid increase in the
incidence of prostate cancer, and prostate cancer became the
seventh most commonly diagnosed cancer in Korean males,
with more than 1,600 cases diagnosed in 2001 (15). Since
the PSA test detects asymptomatic tumors possibly show-
ing excellent prognosis, population-based survival rates could
have increased. These trends are not an artefact, but reflect
the effect of new diagnostic techniques. 
In females, the greatest improvements in survival of com-
mon cancers were observed in stomach and breast cancer.
Stomach and breast cancer were the most common cancers
in Korean females in 2001; there were about 7,500 and
7,000 newly-diagnosed cases, respectively (15).
There were several types of cancers, showing slight decreas-
es or almost no change in survival during 1993-2002. Sur-
vival for pancreatic cancers fell slightly in both males and
females. For lung cancer, the survival rates increased slightly
over the decade. Lack of progress in early detection and treat-
ment could explain no improvement in the survival rates of
lung and pancreas cancers (16). 
However, we should interpret the results of the present
study with caution. Survival trends could be affected by var-
ious factors such as completeness of registration, changes in
definition of disease, and introduction of screening programs
as well as genuine improvements in diagnosis and treatment.
The validity of survival estimates may depend on com-
pleteness of cancer registration (17, 18). In particular, selec-
tive under-ascertainment of patients with a good prognosis
may lead to underestimation of cancer patient survival, whe-
reas an opposite effect could result from selective under-ascer-
tainment of patients with a poor prognosis. One example of
the latter case is the exclusion of DCO cases. 
In our result, DCO %, an important validity index for can-
cer registration data, ranges from 0.5% for the corpus uteri
to 24.7% for the brain and CNS. The ‘‘true’’ survival of cases
registered by DCO is generally poorer than those of others
in the registry population (19). Exclusion of DCO cases may
increase survival estimates, particularly in cancers with pro-
portionately more DCO cases. However, the magnitude of
such increases was known to be generally low (19). 
Compared to the cancer survival of US, survivals of all can-
cers in Korea (37.8% in males, and 57.0% in females dur-
ing 1998-2002) were lower than those of US (66.3 % in
males, and 56.6% in females during 1996-2002) (20). By
contrast, RSRs of much more common cancers in Korea,
such as stomach and cervix uteri, were much higher than
those of US. Compared to the survivals of Japan, RSRs were
lower than those of Japan, but the high RSRs of Japan are
thought to be due to poor completeness of registration in
Japan (21) (Table 4).
Considering the fact that cancer has been the leading cause
of death in Korea since 1980s and newly diagnosed cancer
cases are rapidly increasing, the information on survival pro-
vides clinically useful information for practitioners and can-
cer patients as well as for health policy makers to measure
the effectiveness of cancer treatment. The publication of this
report will be used to prompt more research to identify fac-
tors associated with the observed increases of cancer survival
in Korean population and to compare survival experience
according to socioeconomic status, geographical regions,
and the presence of co-morbidities.
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